Cancer Research AACR Membership EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 68, 615, January 15, 2008. doi: 10.1158/0008-5472.CAN-07-5219
© 2008 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Correction (v68,p1609)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yusuf, N.
Right arrow Articles by Elmets, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yusuf, N.
Right arrow Articles by Elmets, C. A.

Immunology

Protective Role of Toll-like Receptor 4 during the Initiation Stage of Cutaneous Chemical Carcinogenesis

Nabiha Yusuf1,2, Tahseen H. Nasti1, J. Alan Long1, Mohammed Naseemuddin1, Alan P. Lucas1, Hui Xu1 and Craig A. Elmets1,2

1 Department of Dermatology and Skin Diseases Research Center, University of Alabama at Birmingham; 2 Veteran Affairs Medical Center, Birmingham, Alabama

Requests for reprints: Nabiha Yusuf, Department of Dermatology, University of Alabama at Birmingham, 1670 University Boulevard, VH 566A, P. O. Box 202, Birmingham, AL 35294-0019. Phone: 205-934-7432; Fax: 205-934-5745; E-mail: nabiha{at}uab.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Toll-like receptors (TLR) activate multiple steps in inflammatory reactions in innate immune responses. They also activate signals that are critically involved in the initiation of adaptive immune responses. Many tumorigenic chemicals have been associated with endotoxin hypersensitivity mediated through TLR4. To determine the role of TLR4 in cutaneous skin carcinogenesis, we treated TLR4-deficient C3H/HeJ mice and the TLR4-normal C3H/HeN mice with the carcinogenic polyaromatic hydrocarbon 7,12-dimethylbenz(a)anthracene (DMBA). TLR4-deficient C3H/HeJ mice developed more tumors relative to the TLR4-normal C3H/HeN mice. Both C3H/HeN and C3H/HeJ mice developed a T-cell–mediated immune response to topically applied DMBA. Interestingly, the cell-mediated immune response was mediated by IFN-{gamma} in C3H/HeN mice and by interleukin (IL)-17 in C3H/HeJ mice. Moreover, C3H/HeN mice had elevated circulating levels of IFN-{gamma} following topical application of DMBA, whereas IL-17 was elevated in C3H/HeJ mice. The results of this study indicate that TLR4 plays an important role in the prevention of DMBA skin tumorigenesis and that this is associated with differences in the T-cell subtype activated. Efforts to divert the cell-mediated immune response from one that is IL-17 mediated to one that is IFN-{gamma} mediated may prove to be beneficial in the prevention of DMBA-induced cutaneous tumors. [Cancer Res 2008;68(2):615–22]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Toll-like receptors (TLR), a family of molecules that recognize conserved pathogen-associated molecular patterns, have emerged as a key component of the innate immune system. Their ligation leads to the induction of inflammatory responses by transcriptional activation of cytokine, chemokine, and adhesion molecule genes. Mammalian TLRs consist of at least 13 different membrane proteins collectively known as pattern recognition receptors. Some of them are expressed at the cell surface, whereas others are located on the membrane of endocytic vesicles or other intracellular organelles. Individual TLRs differ in their ligand specificity, expression patterns, and signal transduction pathways that they activate (1–3).

Recognition of endogenous ligands by TLRs is now thought to have an important role in the regulation of inflammation, both in infectious and noninfectious diseases (4). This is due in part to the fact that a subset of TLR-induced signals is critically involved in the control of adaptive immune responses (5). There is experimental evidence to suggest that, in some instances, neoplasms may also exploit TLR signaling pathways to advance cancer progression. It has been shown that inflammatory processes promote (rather than initiate) carcinogenesis in a non–cell-autonomous fashion (6). At sites of inflammation, cytokines, chemokines, and matrix-degrading enzymes are released in a persistent unregulated manner predominantly by cells of the innate immune system and these molecules enhance angiogenesis, invasiveness, and survival of premalignant and neoplastic cells (7).

Polyaromatic hydrocarbons, such as 7,12-dimethylbenz(a)anthracene (DMBA), have been used extensively to investigate the mechanisms by which chemicals cause cancer. Although the immune-mediated destruction of the malignant cells is well established, the role of the innate immune system in the development of epithelial malignancies and its potential for immunoprevention has received much less attention (8). The presence of TLRs on resident skin cells may assist in mounting a rapid and efficient host defense against early events in the development of these neoplasms. TLRs are expressed on epidermal cells, including keratinocytes (9, 10), Langerhans cells (11), and dermal mast cells (12). TLRs expressed on human and murine epidermal cells are functional and play an important role in innate immunity in the skin (11, 13).

We have previously reported that application of DMBA to the skin of selected strains of mice results in the development of antigen-specific allergic contact hypersensitivity and that mice in which such a response is present are resistant to tumor development when subjected to a chemical skin carcinogenesis protocol (14). This has lead to the hypothesis that, in addition to the host immune response against chemically induced tumors, there are immunologic influences that target the chemicals that cause the tumors. In other words, we have proposed that contact hypersensitivity to DMBA has a protective effect on skin carcinogenesis by reducing the number of mutant cells that can go on to become tumors.

Because TLRs have an influence on adaptive immune responses and many tumorigenic chemicals have been associated with endotoxin hypersensitivity mediated through TLR4, the purpose of this study was to determine whether TLR4 was involved in DMBA cutaneous carcinogenesis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals and reagents. Female C3H/HeN mice were purchased from Charles River Laboratories. Female C3H/HeJ mice were obtained from The Jackson Laboratory. Mice used for experiments were 6 to 8 weeks of age. All animal procedures were performed according to NIH guidelines under protocols approved by the Institute Animal Care and Use Committee of the University of Alabama at Birmingham.

Hybridoma line XMG1.2 (anti-IFN-{gamma}) was from the American Type Culture Collection and antibody was purified from culture supernatants by affinity chromatography. Normal rat IgG was purchased from Rockland Immunochemicals. Mouse recombinant granulocyte macrophage colony-stimulating factor (GM-CSF), anti-CD3e, streptavidin-phycoerythrin-Cy5, and anti-CD31 (platelet/endothelial cell adhesion molecule) antibodies were purchased from PharMingen and monoclonal rat anti-mouse interleukin (IL)-17 antibody (TC11-18H10) was acquired from Southern Biotechnology. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DMBA, and IL-4 were purchased from Sigma Chemical Co.

Sensitization and elicitation of contact hypersensitivity. The induction and elicitation of contact hypersensitivity in mice were carried out as described (15). Briefly, C3H/HeN and C3H/HeJ mice were sensitized with 100 µL of 0.1% DMBA (w/v in acetone) on their shaved and depilated abdomen on day 0. The mice were challenged on the ear 5 days later. Contact hypersensitivity was measured daily for 5 days beginning 24 h after challenge. To detect the roles of IL-17 and IFN-{gamma} in the elicitation of contact hypersensitivity, mice were injected i.p. with either anti-IL-17 antibody (200 µg) or anti-IFN-{gamma} antibody (400 µg) on days +4 and +5 as described earlier (16). To assess the cytokine profile, mice were sensitized with DMBA (0.1% w/v in acetone) on day 0. On day +5, mice were sacrificed and lymph node cell suspensions were prepared by gentle pressure through a wire mesh screen. Cells were then washed and placed in 96-well culture plates at a concentration of 2 x 105/200 µL in complete medium. Before addition of cells, the plates were coated with anti-CD3 antibody as described previously (17). After an incubation period of 48 h, media were harvested and assayed for cytokine concentrations.

ELISA for cytokine production. Cytokine concentrations in culture medium from bone marrow–derived dendritic cells (BMDC), skin and tumor lysates, and serum were measured using cytokine-specific ELISA using commercial kits from Invitrogen according to the manufacturer's instructions.

Skin tumorigenesis. We used a standard DMBA complete carcinogenesis protocol for this study. DMBA (400 nmol, w/v in acetone) was painted weekly on the shaved and depilated dorsal skin of C3H/HeN and C3H/HeJ mice (15 mice per panel). Mice were evaluated weekly for tumors. Only tumors that had attained a size of ≥1 mm and were present for ≥2 weeks were counted.

Generation of BMDCs. BMDCs were prepared from C3H/HeN and C3H/HeJ mice as described previously (18) with some modifications. Briefly, bone marrow cells were isolated from femurs and tibias. The cells were incubated in RPMI 1640 with a cocktail of antibodies against Iak, CD45R/B220, Lyt-2, and GK1.5 (2 µg/106 cells) on ice for 1 h and washed once with HBSS after lysis of RBCs. Different cellular populations were removed from suspension by antibody-mediated depletion using sheep anti-rat IgG dynabeads according to the manufacturer's instructions. Cells were washed once with HBSS and cultured in 10% FCS-RPMI 1640 supplemented with recombinant mouse GM-CSF (10 ng/mL) and IL-4 (10 ng/mL) in six-well plates (5 x 105 per well). On day 6, half of the medium was replaced with fresh medium and cells were incubated in culture with polymyxin B (10 µg/mL) to prevent lipopolysaccharide (LPS) contamination. After 24 h of culture at 37°C in the presence of 5% CO2, culture media were collected and evaluated for cytokines.

Preparation of tissue lysates. The back skin samples were scraped of s.c. fat and washed with PBS. Both skin and tumors were collected from at least four mice and homogenized in ice-cold lysis buffer [50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L EGTA, 1 mmol/L EDTA, 20 mmol/L NaF, 100 mmol/L Na3VO4, 0.5% NP40, 1% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride (pH 7.4)] with freshly added protease inhibitor cocktail (Protease Inhibitor Cocktail, Sigma Chemical). The homogenate was then centrifuged at 14,000 x g for 25 min at 4°C and the supernatant (total cell lysate) was collected, aliquoted, and stored at –80°C. The protein content in the lysates was measured with a detergent-compatible Bio-Rad assay according to the manufacturer's protocol.

Proliferation assay in tumor cells. The proliferative potential of tumor cells obtained from TLR-deficient C3H/HeJ and C3H/HeN mice was assessed using the MTT assay as described previously (19). Tumor cells were cultured as described by Maeda et al. (20) with some modifications. Briefly, tumor pieces of <2 mm3 in size were seeded into culture plates and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% MEM nonessential amino acid, and 1% antibiotic/penicillin-streptomycin solution. When the cultures had reached 80% confluence, the adherent cells were detached with 0.1% trypsin/0.05% EDTA (Life Technologies) and used for subsequent passage. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. Cells were harvested and seeded in triplicate into 96-well plates at a density of 2 x 104 per well. At 0, 1, 2, or 3 days after seeding, MTT solution was added to each well followed by incubation for 2 h at 37°C. After incubation, DMSO was added to each well. Spectrophotometric absorbance of each sample was measured at 540 nm using a microplate reader (Bio-Rad).

Assessment of expression of vascular endothelial cell antigen, CD31. Immunostaining for CD31 was done on frozen tumor sections from C3H/HeJ and C3H/HeN mice. Briefly, frozen sections (5 µm thick) were fixed in cold acetone and nonspecific binding sites were blocked by immersing the sections in Tris-HCl buffer containing 5% goat serum and bovine serum albumin (0.5% w/v). The sections were then incubated with monoclonal antibodies specific for CD31 for 1 h. Antibody binding was detected by subsequent incubation of sections with streptavidin-phycoerythrin-Cy5 secondary antibody for 1 h. After washing, the sections were counterstained with Hoechst 33342, which stains nuclei. The intensity of the staining was evaluated using a microscope equipped for immunofluorescence analysis.

Statistical analysis. The differences between experimental groups for contact hypersensitivity and cytokine ELISAs were analyzed using the Student's t test. The Fisher's exact test was used for analysis of the tumors per group and the percentage of mice with tumors. In all cases, a P < 0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Contact hypersensitivity in TLR4-deficient mice is mediated mainly by IL-17. Topical application of the carcinogenic polyaromatic hydrocarbon DMBA results in the development of antigen-specific contact hypersensitivity (15). To determine whether TLR4 influences contact hypersensitivity to DMBA, panels of C3H/HeN and C3H/HeJ mice were sensitized to that agent and the contact hypersensitivity response in the two strains was compared. Both strains developed contact hypersensitivity to DMBA and the magnitude of the ear swelling response in the two strains was comparable (P > 0.05; Fig. 1A and B ).


Figure 1
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. DMBA contact hypersensitivity and cytokine profile in TLR4-deficient C3H/HeJ (A) and C3H/HeN (B) mice. C3H/HeN and C3H/HeJ mice were sensitized with DMBA and ear challenged 5 d later as described in Materials and Methods. The magnitude of contact hypersensitivity response was comparable in both groups of mice (P > 0.05). C, the draining lymph nodes were harvested 5 d after sensitization and lymph node cell suspension from C3H/HeJ and C3H/HeN mice was prepared as described in Materials and Methods. Points, mean of three mice per group; bars, SE. Each experiment was repeated twice. Cells were then stimulated with anti-CD3 antibody. Cytokine levels were measured by ELISA. Lymph node cells from DMBA-sensitized C3H/HeN mice secreted significantly higher levels (*, P < 0.05) of IFN-{gamma} (C), whereas C3H/HeJ mice secreted significantly higher levels (*, P < 0.05) of IL-17 (D). Columns, mean of three mice per group; bars, SD. Each experiment was repeated twice.

 
Effector T cells for contact hypersensitivity to other haptens have been shown to produce IFN-{gamma} and IL-17 (16, 17). To determine the influence of TLR4 on the cytokine pattern of the effector T cells, DMBA-sensitized lymph node cells were isolated and placed in culture in anti-CD3-coated plates. Media were removed 48 h later and examined for secreted IFN-{gamma} and IL-17 by ELISA. Cells from C3H/HeN sensitized mice produced significantly greater amounts of IFN-{gamma} (P < 0.05) than C3H/HeJ mice (Fig. 1C). In contrast, the amount of secreted IL-17 produced by lymph node cells from DMBA-sensitized C3H/HeN mice was not significantly greater than that produced by cells from naive mice. In contrast, there was a marked increase in IL-17 (P < 0.05) secretion by lymph node cells from DMBA-sensitized C3H/HeJ mice (Fig. 1D). These results indicated that inactivation of TLR4 shifts that balance from IFN-{gamma}–producing cells to those that produce IL-17.

To examine the importance of IL-17 or IFN-{gamma} in vivo in DMBA contact hypersensitivity, C3H/HeN and C3H/HeJ mice were sensitized to DMBA and then treated with either anti-IL-17, anti-IFN-{gamma} antibodies, or rat IgG (as a control) before challenge. The contact hypersensitivity response was significantly inhibited in C3H/HeN mice (P < 0.05) when treated with anti-IFN-{gamma} antibody (Fig. 2A ). In contrast, treatment of C3H/HeJ mice, which are deficient in TLR4, with neutralizing anti-IFN-{gamma} antibody (400 µg/mouse) did not show a significant inhibitory effect (Fig. 2B). On the other hand, treatment with anti-IL-17 (200 µg/mouse) had no effect on DMBA contact hypersensitivity in C3H/HeN mice (Fig. 2C), whereas in C3H/HeJ mice the contact hypersensitivity response was significantly inhibited (P < 0.05) compared with controls treated with normal rat IgG at the same dose (Fig. 2D).


Figure 2
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. TLR4-deficient C3H/HeJ mice and TLR4-normal C3H/HeN mice mediate the contact hypersensitivity response to DMBA by different effector cells. Panels of mice (four mice per panel) were sensitized to DMBA after treatment with either anti-IFN-{gamma} or anti-IL-17 antibodies and then ear challenged 5 d later as described in Materials and Methods. In vivo treatment with IFN-{gamma} antibodies produced significantly greater inhibition of contact hypersensitivity in C3H/HeN mice (A) than in C3H/HeJ mice (B). In contrast, in vivo treatment with anti-IL-17 antibodies produced significantly greater inhibition of contact hypersensitivity in C3H/HeJ mice (D) compared with C3H/HeN mice (C). Points, mean of three mice per group; bars, SE. Each experiment was repeated twice with similar results.

 
TLR4-deficient mice are more susceptible to cutaneous DMBA carcinogenesis. The role of TLR4 in DMBA cutaneous carcinogenesis was next investigated by comparing C3H/HeN and C3H/HeJ mice for tumor development. The two strains were subjected to a complete carcinogenesis protocol in which DMBA was applied weekly to the skin. The number of tumors was significantly greater (P < 0.05) in C3H/HeJ mice compared with C3H/HeN mice (Fig. 3A ). Similar results were obtained when the data were evaluated as the cumulative number of tumors and the number of tumors per tumor-bearing mouse (data not shown). Although all animals in both strains eventually developed tumors with this protocol, they arose more rapidly in TLR4-deficient C3H/HeJ mice. For example, by week 7, 100% of C3H/HeJ mice had developed tumors, whereas only 20% of C3H/HeN mice had tumors, and these differences were significant (P < 0.05; Fig. 3B). The tumors from C3H/HeJ mice grew progressively and showed a significant (P < 0.05) increase in volume compared with tumors from C3H/HeN mice (Fig. 3C).


Figure 3
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. TLR4-deficient C3H/HeJ mice are more susceptible to DMBA-induced carcinogenesis than TLR-normal C3H/HeN mice. Mice were subjected to a complete cutaneous carcinogenesis protocol (15 mice per panel) using DMBA as described in Materials and Methods. A, the number of tumors per group was plotted as a function of the number of weeks on the test. There were significantly more tumors in C3H/HeJ mice (*, P < 0.05) than in C3H/HeN mice. B, the percentage of mice with tumors was plotted as a function of the number of weeks of the test. By the 7th week, 100% of C3H/HeJ mice had tumors compared with 20% of C3H/HeN mice. C, tumors from C3H/HeJ mice were significantly larger (*, P < 0.05) in volume than tumors from C3H/HeN mice. D, proliferative capacity of tumor cells from DMBA-induced skin tumors. Tumor cells were obtained from DMBA-induced tumors from C3H/HeN or C3H/HeJ mice and subjected to a MTT assay immediately and 1, 2, or 3 d after having been placed in culture as described in Materials and Methods. Proliferative potential of tumor cells is expressed in terms of absorbance of each sample. The proliferative capacity was higher (*, P < 0.05) in tumor cells obtained from C3H/HeJ mice when compared with tumor cells derived from C3H/HeN mice. Columns, mean of triplicate cultures; bars, SD. Each experiment was repeated thrice.

 
Tumor cell lines from TLR4-deficient mice show an increase in proliferative capacity. To study the growth behavior of the DMBA-induced tumors, tumor specimens were obtained from both C3H/HeJ and C3H/HeN mice. Tumor pieces of <2 mm3 were seeded into culture plates and cultured as described in Materials and Methods. When the cultures had reached 80% confluence, the adherent cells were detached with 0.1% trypsin/0.05% EDTA and used for subsequent passage. To determine their capacity to proliferate, cell lines were subjected to a MTT proliferation assay, which was done immediately or at 1, 2, and 3 days after seeding. In all samples tested, the proliferative capacity was higher (P < 0.05) in cell lines obtained from DMBA-treated C3H/HeJ mice compared with cell lines developed in C3H/HeN mice (Fig. 3D).

TLR4-deficient mice express higher levels of IL-17 and lower levels of IFN-{gamma} after DMBA carcinogenesis. Because IFN-{gamma} and IL-17 have an influence on development of the DMBA contact hypersensitivity response, we also assessed their role during DMBA-induced tumor development. Tumor, skin, and blood samples were collected from C3H/HeJ and C3H/HeN mice after 25 weeks on the DMBA skin tumorigenesis protocol. At 25 weeks, serum from these mice showed a slight but significant increase in IFN-{gamma} (P < 0.05) in C3H/HeN mice compared with C3H/HeJ mice. Conversely, there was a significant decrease in IL-17 (P < 0.001) production in C3H/HeN mice compared with C3H/HeJ mice (Fig. 4A and C ). These differences in cytokine levels were accentuated in tumor lysates. C3H/HeN mice showed a much greater increase in IFN-{gamma} (P < 0.001) and a greater reduction in IL-17 (P < 0.05) than in C3H/HeJ mice (Fig. 4B and D). The greater differences in tumor cytokine levels likely reflect the selective accumulation of T cells producing IFN-{gamma} and IL-17 in tumors from C3H/HeN and C3H/HeJ mice, respectively.


Figure 4
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Tumor-bearing TLR4-deficient C3H/HeJ mice produce less IFN-{gamma} and more IL-17 than TLR4-normal C3H/HeN tumor-bearing mice. Cytokines were measured in serum, and skin and tumor lysates from mice after having been subjected to a DMBA cutaneous carcinogenesis protocol for 25 wk. C3H/HeN mice showed higher levels of IFN-{gamma} in their serum (A) and skin and tumor lysates (B) compared with C3H/HeJ mice. C3H/HeJ mice showed higher levels of IL-17 in their serum (C) and skin and tumor lysates (D; *, P < 0.05) compared with C3H/HeJ mice. Columns, mean of panels containing four mice per group; bars, SD. Each experiment was repeated twice with similar results. *, P < 0.05; **, P < 0.001.

 
TLR4-deficient mice express higher levels of IL-23 and lower levels of IL-12 after DMBA carcinogenesis and are more prone to angiogenesis. BMDCs from DMBA-treated C3H/HeJ mice secreted smaller amounts of IL-12 (P < 0.05) and more IL-23 (P < 0.05) than C3H/HeN mice (Fig. 5A and B ). Similar patterns of circulating cytokines IL-12 (P < 0.05) and IL-23 (P < 0.05) were found in the serum of DMBA-treated C3H/HeN and C3H/HeJ mice (Fig. 5C and D).


Figure 5
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Tumor-bearing TLR4-deficient C3H/HeJ mice secrete less IL-12 and more IL-23 than TLR4-normal C3H/HeN tumor-bearing mice. Cytokines were measured in medium from cultured BMDCs and serum from mice after having been subjected to a DMBA cutaneous carcinogenesis protocol for 25 wk. A, BMDCs from C3H/HeN mice secrete higher levels of IL-12 compared with C3H/HeJ mice. B, C3H/HeJ mice showed higher levels of IL-23 compared with C3H/HeN mice. C, C3H/HeN mice showed higher levels of IL-12 in their serum compared with C3H/HeJ mice. D, C3H/HeJ mice showed higher levels of IL-23 in their serum compared with C3H/HeJ mice. Columns, mean of four mice per group; bars, SD. Each experiment was repeated thrice. *, P < 0.05.

 
Because TLR4-deficient C3H/HeJ mice had higher levels of IL-17 in their serum and tumors and C3H/HeN mice had greater amounts of IL-12 and IFN-{gamma}, we were interested in determining whether angiogenic growth factors vascular endothelial growth factor (VEGF), macrophage inflammatory protein-2 (MIP-2), and keratinocyte chemoattractant (KC) levels lead to an increase in tumor angiogenesis in C3H/HeJ mice than in C3H/HeN mice. We observed that this was the case; following treatment with DMBA, VEGF (P < 0.05), MIP-2 (P < 0.001), and KC (P < 0.05) levels in tumor lysates were significantly higher in C3H/HeJ mice than in C3H/HeN mice (Fig. 6A–C ).


Figure 6
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. TLR4 deficiency promotes angiogenesis. Angiogenic factors VEGF, MIP-2, and KC were measured in tumor lysates after 25 wk from mice placed on a DMBA cutaneous carcinogenesis protocol. TLR4-deficient C3H/HeJ mice showed significantly higher levels of VEGF (A), MIP-2 (B), and KC (C) compared with TLR4-normal C3H/HeN mice. Columns, mean of four mice per group; bars, SD. Each experiment was repeated thrice. D, the expression level of CD31 in DMBA-induced tumors was greater in C3H/HeJ mice compared with C3H/HeN mice. Samples of tumors were examined for CD31 fluorescence staining. Representative photomicrographs are shown from experiments conducted in tumor samples from at least five mice in each group. Identical patterns were observed in all of the tumors examined. CD31-positive staining is indicated by bright pink fluorescence. Bar, 50 µm. *, P < 0.05; **, P < 0.001.

 
We next assessed the extent of neovascularization of the tumors by examination of the expression of CD31, which is known to contribute to the formation of new vasculature and is used as a biomarker of angiogenesis (21). The intensity of the CD31 immunofluorescent staining was increased in the DMBA-induced tumors of C3H/HeJ mice tumors compared with C3H/HeN mice (Fig. 6D).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Positional cloning of the locus responsible for LPS hyporesponsiveness in C3H/HeJ mice and generation of TLR4 knockout mice have shown that TLR4 is essential for LPS signaling (22). In addition to activation by LPS signaling, TLR4 is also associated with signaling by many environmental chemicals, many of which are tumorigenic (23). Stimulation of TLRs by various ligands leads to signaling pathways that activate not only innate but also adaptive immunity by antigen-presenting cell (APC)-dependent or APC-independent mechanisms (5).

In previous studies from our laboratory, it has been shown that topical application of the carcinogenic polyaromatic hydrocarbon DMBA results in the development of antigen-specific contact hypersensitivity (15). We had also proposed that the allergic contact hypersensitivity response to DMBA that occurs in some strains of mice serves to protect those animals against the carcinogenic activities of that compound. This hypothesis is based in part on observations that there is an inverse relationship between cell-mediated immunity to DMBA and the number of tumors that develop in C3H/HeN and C3H.SW mice, MHC congenic mice (14). We have also observed that mice deficient in CD4+ T cells are resistant to the development of DMBA-induced skin tumors than normal mice, whereas mice deficient in CD8+ T cells are more likely to develop them.3 The results of these studies support that hypothesis with modifications. Although the magnitude of the contact hypersensitivity response in both C3H/HeN and C3H/HeJ mice was equivalent, C3H/HeJ mice were more susceptible to DMBA skin tumorigenesis, whereas C3H/HeN mice were not. However, the DMBA contact hypersensitivity response in C3H/HeN mice was mediated primarily by IFN-{gamma}–producing T cells and in C3H/HeJ mice by IL-17–producing T cells.

Based on these findings, a more appropriate hypothesis for the relationship between T-cell immunity to DMBA and the initiation of DMBA skin carcinogenesis is that mice that develop a cell-mediated immune response to DMBA in which the effector cells are IFN-{gamma}–producing T cells will be resistant to DMBA skin tumorigenesis but those that have IL-17 effector T cells or do not develop a contact hypersensitivity response at all will be susceptible to the carcinogenic activities of that agent.

Our results extend those observations by providing evidence that TLR4 determines the type of effector T cell that is generated following topical application of hapten. An intact TLR4 signaling pathway results in IFN-{gamma}–producing effector T cells, whereas a defect in the TLR4 signaling pathway leads to the generation of IL-17–producing effector T cells. These two types of effector T cells have distinct activities. Although both are effective at producing DMBA contact hypersensitivity, only the IFN-{gamma}–producing T cells confer resistance to DMBA tumorigenesis. An obvious question is whether the controlling role that TLR4 has in determining the types of effector T cells that develop applies to other contact allergens. Our preliminary studies indicate that it does. Contact hypersensitivity to dinitrofluorobenzene also occurs in both C3H/HeN and C3H/HeJ mice and is mediated primarily by IL-17 cells in C3H/HeJ mice but by cells that produce IFN-{gamma} in C3H/HeN mice (data not shown). Effector T cells for contact hypersensitivity to other haptens have been shown to produce IFN-{gamma} and IL-17 (16, 17).

The process by which TLR4 leads to the preferential activation of IFN-{gamma}–producing T cells is apt to be a multistep process. We observed that IL-12 levels were much greater (P < 0.05) in serum of C3H/HeN than in C3H/HeJ mice. IL-12 has been shown to encourage the development of IFN-{gamma} T cells. On the other hand, IL-23 is required for IL-17–producing T cells (24, 25). Thus, TLR4-induced suppression of IL-23 and the unimpeded production of IL-12 is likely to be a step in this process. IL-17 has been shown to increase the growth of several different types of tumors (24, 26–28). It has been proposed that this is due at least in part to its proangiogenic effects (24, 27). On the other hand, IL-12 and IFN-{gamma}, which were produced in greater amounts in C3H/HeN mice, have antiangiogenic properties. IL-17 up-regulates elaboration of various proangiogenic factors and modulates production of KC, MIP-2, and VEGF by fibroblasts. IL-17 might be a potential contributor to the inflammatory angiogenesis via induction of proangiogenic factors by stromal fibroblasts (29).

If it is true that IFN-{gamma}–producing T cells are important effector cells for DMBA contact hypersensitivity and those cells are involved in reducing the development of DMBA-induced tumors, then it may be possible to use this information to develop methods that augment the induction of IFN-{gamma}–producing T cells at the expense of IL-17–producing effector T cells and regulatory T cells that have a permissive role of chemical carcinogenesis.


   Acknowledgments
 
Grant support: NIH grant P30 AR050948 (C.A. Elmets), Veterans Administration Merit Review Award 18-103-02 (C.A. Elmets), and Department of Defense.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
3 N. Yusuf et al., unpublished data. Back

Received 9/ 7/07. Revised 10/26/07. Accepted 11/ 7/07.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783–801.[CrossRef][Medline]
  2. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1–16.[Medline]
  3. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7:179–90.[CrossRef][Medline]
  4. Rifkin IR, Leadbetter EA, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005;204:27–42.[CrossRef][Medline]
  5. Iwasaki A, Medzhitov R. Toll like receptor control of the adaptive immune response. Nat Immunol 2004;5:987–95.[CrossRef][Medline]
  6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–7.[CrossRef][Medline]
  7. Killeen SD, Wang JH, Andrews EJ, et al. Exploitation of the Toll-like receptor system in cancer: a double edged sword? Br J Cancer 2006;95:247–52.[CrossRef][Medline]
  8. Woods GM, Malley RC, Muller HK. The skin immune system and the challenge of tumour immunosurveillance. Eur J Dermatol 2005;15:63–9.[Medline]
  9. Miller LS, Modlin R. Human keratinocyte Toll-like receptors promote distinct immune responses. J Invest Dermatol 2007;127:262–3.[CrossRef][Medline]
  10. Lebre MC, Angelic MG, van der Aar L, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007;127:331–41.[CrossRef][Medline]
  11. Mitsui H, Watanabe T, Saeki H, et al. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol 2004;122:95–102.[CrossRef][Medline]
  12. Matsushima H, Yamada N, Matsue H, et al. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004;173:531–41.[Abstract/Free Full Text]
  13. Kawai K, Shimura H, Minagawa M, et al. Expression of functional Toll-like receptor 2 on human epidermal keratinocytes. J Dermatol Sci 2002;30:185–94.[CrossRef][Medline]
  14. Yusuf N, Timares L, Seibert MD, et al. Acquired and innate immunity to polyaromatic hydrocarbons. Toxicol Appl Pharmacol 2007;224:308–12.[CrossRef][Medline]
  15. Klemme JC, Mukhtar H, Elmets CA. Induction of contact hypersensitivity to dimethylbenz(a)anthracene and benzo(a)pyrene in C3H/HeN mice. Cancer Res 1987;47:6074–8.[Abstract/Free Full Text]
  16. He D, Wu L, Kim HK, et al. CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol 2006;177:6852–8.[Abstract/Free Full Text]
  17. Xu H, DiIulio N, Fairchild R. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon {gamma}-producing (Tc1) effector CD8+ T cells and interleukin (IL) 4/IL-10-producing (Th2) negative regulatory CD4+ T cells. J Exp Med 1996;183:1001–12.[Abstract/Free Full Text]
  18. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693–702.[Abstract/Free Full Text]
  19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.[CrossRef][Medline]
  20. Maeda A, Schneider SW, Kojima M, et al. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 2006;66:2962–9.[Abstract/Free Full Text]
  21. Risau W. Differentiation of endothelium. FASEB J 1995;9:926–33.[Abstract]
  22. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 2003;35:555–62.[CrossRef][Medline]
  23. Elmets CA, Athar M, Tubesing KA, et al. Susceptibility to the biological effects of polyaromatic hydrocarbons is influenced by genes of the major histocompatibility complex. Proc Natl Acad Sci U S A 1998;95:14915–9.[Abstract/Free Full Text]
  24. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175:6177–89.[Abstract/Free Full Text]
  25. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461–5.[CrossRef][Medline]
  26. Honorati MC, Neri S, Cattini L, et al. IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol 2003;133:344–9.[CrossRef][Medline]
  27. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620–7.[Abstract/Free Full Text]
  28. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114–21.[Abstract/Free Full Text]
  29. Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-{alpha}-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004;93:39–43.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Vet PatholHome page
A. K. Bauer and E. A. Rondini
REVIEW PAPER: The Role of Inflammation in Mouse Pulmonary Neoplasia
Vet. Pathol., May 1, 2009; 46(3): 369 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Yusuf, T. H. Nasti, S. K. Katiyar, M. K. Jacobs, M. D. Seibert, A. C. Ginsburg, L. Timares, H. Xu, and C. A. Elmets
Antagonistic Roles of CD4+ and CD8+ T-Cells in 7,12-Dimethylbenz(a)anthracene Cutaneous Carcinogenesis
Cancer Res., May 15, 2008; 68(10): 3924 - 3930.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Correction: TLR4 in Cutaneous DMBA Carcinogenesis
Cancer Res., March 1, 2008; 68(5): 1609 - 1609.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Correction (v68,p1609)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yusuf, N.
Right arrow Articles by Elmets, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yusuf, N.
Right arrow Articles by Elmets, C. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online